文献速递肝病消化道肿瘤与早癌

肝细胞癌的分子与免疫图景指导治疗决策

Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making.
PubMed 文献 · Hepatology · 2023-06-12

本文综述肝细胞癌(HCC)在肿瘤间及肿瘤内存在的组织学和分子异质性,以及单细胞和空间组学技术对这些异质性的解析。文章讨论HCC分子与免疫图景作为生物标志物的潜力、预测/预后生物标志物的评估与临床应用框架,以及正在进行的生物标志物指导的治疗临床试验。

要点

  • HCC存在肿瘤间和肿瘤内异质性,可影响疾病进展自然史及靶向分子和免疫通路新疗法的疗效。
  • 单细胞和空间组学技术可解析癌细胞及肿瘤免疫微环境的异质性,有助于发现生物标志物。
  • 伴随生物标志物可优化HCC各分期治疗算法,但异质性和治疗方案的复杂性使临床评估与转化面临挑战。

核心结论

  • 全面刻画HCC不同层次的异质性可能促进发现生物标志物,以支持个体化、合理的治疗决策并优化疗效、减少不良反应风险。
  • 伴随生物标志物可优化有限医疗资源的分配,改进HCC各分期的治疗算法;但异质性的复杂性和不断扩展的治疗药物与方案清单使生物标志物的临床评估和转化日益具有挑战性。

研究设计与样本

  • 本文为综述,讨论HCC分子与免疫图景的最新发现作为生物标志物的潜力与效用、预测/预后生物标志物评估与临床应用的框架,以及正在进行的生物标志物指导的治疗临床试验。

主要发现

  • HCC在肿瘤间和肿瘤内存在组织学和分子异常的高度异质性,可能导致疾病进展自然史的多样性和患者间的临床差异。
  • 新近开发的多模态、单细胞和空间组学分析技术使得研究癌细胞及肿瘤免疫微环境的肿瘤间/肿瘤内异质性成为可能。
  • 这些异质性特征可能影响针对新分子和免疫通路的新兴疗法的自然史和疗效,其中一些通路曾被认为不可成药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出肿瘤间/肿瘤内异质性的复杂性以及不断扩展的治疗药物和方案清单使生物标志物的临床评估与转化日益具有挑战性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Liver cancer, primarily HCC, exhibits highly heterogeneous histological and molecular aberrations across tumors and within individual tumor nodules. Such intertumor and intratumor heterogeneities may lead to diversity in the natural history of disease progression and various clinical disparities across the patients. Recently developed multimodality, single-cell, and spatial omics profiling technologies have enabled interrogation of the intertumor/intratumor heterogeneity in the cancer cells and the tumor immune microenvironment. These features may influence the natural history and efficacy of emerging therapies targeting novel molecular and immune pathways, some of which had been deemed undruggable. Thus, comprehensive characterization of the heterogeneities at various levels may facilitate the discovery of biomarkers that enable personalized and rational treatment decisions, and optimize treatment efficacy while minimizing the risk of adverse effects. Such companion biomarkers will also refine HCC treatment algorithms across disease stages for cost-effective patient management by optimizing the allocation of limited medical resources. Despite this promise, the complexity of the intertumor/intratumor heterogeneity and ever-expanding inventory of therapeutic agents and regimens have made clinical evaluation and translation of biomarkers increasingly challenging. To address this issue, novel clinical trial designs have been proposed and incorporated into recent studies. In this review, we discuss the latest findings in the molecular and immune landscape of HCC for their potential and utility as biomarkers, the framework of evaluation and clinical application of predictive/prognostic biomarkers, and ongoing biomarker-guided therapeutic clinical trials. These new developments may revolutionize patient care and substantially impact the still dismal HCC mortality.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Dhanasekaran R, Suzuki H, Lemaitre L, et al. Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making. Hepatology. 2023. PMID: 37300379. doi:10.1097/HEP.0000000000000513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。